Top line data on the ATTRACT study

It’s been a very busy few months at Vicore as we’ve continued to progress our studies into IPF and of course our COVID study, ATTRACT.

As we now have some initial top line positive results from ATTRACT, we asked CMO Rohit Batta to talk about what the ATTRACT results might mean for COVID treatment, and if there is correlation from these results to our ongoing studies into rare lung diseases.

Back to news

Read more posts

Related posts

C21 shows promise against COVID-19 where other drugs have failed

Vicore’s ATTRACT study shows promise for novel drug C21 against COVID-19 in hospitalised patients

Idiopathic Pulmonary Fibrosis (IPF) – weathering the pandemic

Untangling the dualistic components of the RAS in PF the Yin and Yang

Interview with Ella Radvogin, Clinical Psychologist at Alex Therapeutics